Success Metrics

Clinical Success Rate
93.3%

Based on 14 completed trials

Completion Rate
93%(14/15)
Active Trials
0(0%)
Results Posted
86%(12 trials)
Terminated
1(7%)

Phase Distribution

Ph phase_1
5
33%
Ph phase_2
9
60%
Ph phase_3
1
7%

Phase Distribution

5

Early Stage

9

Mid Stage

1

Late Stage

Phase Distribution15 total trials
Phase 1Safety & dosage
5(33.3%)
Phase 2Efficacy & side effects
9(60.0%)
Phase 3Large-scale testing
1(6.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

93.3%

14 of 15 finished

Non-Completion Rate

6.7%

1 ended early

Currently Active

0

trials recruiting

Total Trials

15

all time

Status Distribution
Completed(14)
Terminated(1)

Detailed Status

Completed14
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
15
Active
0
Success Rate
93.3%
Most Advanced
Phase 3

Trials by Phase

Phase 15 (33.3%)
Phase 29 (60.0%)
Phase 31 (6.7%)

Trials by Status

completed1493%
terminated17%

Recent Activity

Clinical Trials (15)

Showing 15 of 15 trials
NCT02689206Phase 2

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Switched From a Stable Dose of an Erythropoiesis-stimulating Agent

Completed
NCT02829320Phase 3

Efficacy and Safety Study of GSK1278863 in Japanese Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Erythropoiesis Stimulating Agents

Completed
NCT01831804Phase 1

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Single and Repeated Doses of Topical GSK1278863

Completed
NCT02243306Phase 1

Study to Assess the Pharmacokinetics of GSK1278863 in Subjects With End Stage Renal Disease Undergoing Peritoneal Dialysis

Completed
NCT01977573Phase 2

A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)

Completed
NCT01977482Phase 2

Evaluation of Dose Response Relationship, Safety and Efficacy of GSK1278863 in Hemodialysis-dependent Subjects With Chronic Kidney Disease Associated Anemia

Completed
NCT02019719Phase 2

Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Japanese Hemodialysis-Dependent Subjects With Anemia Associated With Chronic Kidney Disease

Completed
NCT01920594Phase 2

Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair

Completed
NCT01587924Phase 2

4 Week Switch Study in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease

Completed
NCT01587898Phase 2

4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis

Completed
NCT02135848Phase 2

3 Month PHI PAD PoM Study

Completed
NCT02075463Phase 2

Study to Evaluate the Safety and Efficacy of GSK1278863 in Recombinant Human Erythropoietin (rhEPO) Hyporesponsive Hemodialysis-dependent Chronic Kidney Disease Subjects With Anemia

Terminated
NCT01673555Phase 1

Effects of GSK1278863A on Pulmonary Artery Pressure in Healthy Volunteers

Completed
NCT01376232Phase 1

Study to Assess the Pharmacokinetics of GSK1278863A Coadministered With a High Fat Meal or an Inhibitor of CYP2C8 (Gemfibrozil)

Completed
NCT02231190Phase 1

GSK1278863 Effects on Eccentric Exercise-Induced Muscle Damage

Completed

All 15 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
15